Daily Archives: March 10, 2020

Armenia’s electronic health record journey is strengthened through membership in SNOMED International and commitment to SNOMED CT’s clinical terminology

London, United Kingdom, March 10, 2020 (GLOBE NEWSWIRE) — As 2019 drew to a close, the Republic of Armenia’s Ministry of Health signed on as a Member of the SNOMED International community.

The Ministry of Health of the Republic of Armenia elaborates and implements the policies of the Republic in the healthcare sector.  The Republic holds authority for the implementation of Armenia’s e-Health system, a single information platform supporting stakeholders of the country’s medical institutions, citizens, and the state healthcare providers.  The goal of the system is the usage of modern information and communication technologies, providing high-quality, safe, accessible and cost-effective medical services to the public; Tenets of which SNOMED CT supports in full.

With a roadmap introduced by the Minister of Health at the end of 2017, SNOMED CT is well positioned to support the implementation of Armenia’s unified electronic information system approach through the provision of clinical terminology.  Through the contribution of a structured clinical terminology, Armenia can leverage SNOMED CT to support delivery of projected system outcomes including the accuracy and relevancy of clinical information, a reduction in clinical miscommunication, and the ability to effectively use data to drive system-wide care decisions.

SNOMED CT is the world’s most comprehensive health terminology.  Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization.  The addition of Armenia as a Member has grown the organization’s membership reaching further into Eurasia, now representing nine countries in the Asia Pacific region.

“We are exceedingly pleased to be able to play a role in the Republic of Armenia’s national electronic information system implementation”, offers SNOMED International CEO, Don Sweete. “Through Protocol Decision no 43 and a definitive roadmap, Armenia sets its sights to improve the effectiveness, transparency and accuracy of health care interactions for their citizens, something that SNOMED International is proud to take part in progressing.”

Since 2017, the Government of Armenia has dynamically installed e-health system in all hospitals throughout the country.  In this ongoing process to achieve great results, the Ministry of Health of Armenia adopted a policy of integration of the data to be accurate, reliable and complete.  For this reason, Armenia joined SNOMED International as a member country in 2019 to promote health information coding, health research and health records. Future integration and sharing of data will enhance and support clinical decisions and planning health policy.

The Government of Armenia strongly has a belief that integration of SNOMED CT will not only support more accurate clinical decisions, but will also enhance productivity and patient safety.  This is one step forward to unifying different local health systems.

Armenia’s membership heightens the capability for clinical interoperability within the Asia Pacific region as well as leverages knowledge sharing among regional and international counterparts.  SNOMED CT is part of the national infrastructure to ensure the exchange of accurate, relevant and timely information across all the information systems to support direct care, self-care and secondary uses of health information.

To learn more about SNOMED International, SNOMED CT and new Member Armenia, visit www.snomed.org.

About SNOMED International:

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

Attachment

Kelly Kuru
SNOMED International
1 416 566 8725
kku@snomed.org

Tamara Minasyan
Ministry of Health, Republic of Armenia
minatama@gmail.com

Algernon Announces Coronavirus Update Featured on BioPub Hosted by Dr. KSS MD PhD

VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that BioPub recently hosted an interview by Dr. KSS of the Company’s CEO and CSO. The 35 minute interview provides additional insight into the Company’s recent developments surrounding COVID-19 (coronavirus) and the potential of NP-120 (Ifenprodil) as a possible therapeutic treatment.

The interview can be accessed through the following link: https://youtu.be/K7y05y_N4ow

The Company invites interested shareholders, investors, members of the media and the public to listen to the update.
 
About BioPub

BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don’t get and presence at meetings others don’t bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.

About Algernon Pharmaceuticals Inc. 

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No securities regulatory authority or stock exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the closing of the Offering, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

GCP Applied Technologies Signs VERIFI® Deal with Singapore Concrete Technology Innovator Pan-United Concrete Pte. Ltd.

Extends global position of VERIFI® in-transit concrete management system through expanded partnership with Singapore’s largest concrete and cement provider

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) — GCP Applied Technologies Inc. (NYSE: GCP), a leading global provider of construction products technologies, today announced that it has reached an agreement with Pan-United Concrete Pte. Ltd., a wholly-owned subsidiary of Singapore-listed Pan-United Corporation Ltd., the country’s largest concrete and cement provider. The agreement implements GCP’s VERIFI® in-transit concrete management system for use in more than 300 of Pan-United’s fleet of concrete mixer trucks in the Singapore market.

“Our agreement with Pan-United is an important step in expanding the global reach of our VERIFI® in-transit concrete management system and strengthening our position in the Asia Pacific market,” said Dr. Boudewijn Van Lent, GCP’s EVP of Specialty Construction Chemicals. “Pan-United is a global leader and proven concrete technology innovator, and we are pleased to build our partnership and continue to improve the quality, consistency and efficiency of how concrete is delivered.”

The VERIFI® in-transit concrete management system provides sophisticated, automated process monitoring and control during transit from the ready-mix concrete plant to the jobsite by using sensors installed on concrete mixer trucks to monitor, measure and manage concrete properties in-transit. The VERIFI® system offers a new level of concrete quality control and helps increase product consistency from one truck to the next to reduce rejected loads, increase jobsite efficiency and minimize costly project delays. In addition, the technology offers several environmental benefits including the potential for less cement usage and reduced waste as well as increased fuel efficiency.

“The VERIFI® system is a breakthrough innovation in the construction industry. It sets higher standards for concrete quality, workability management and consistency. It also improves the productivity of our operations and demonstrates our commitment to sustainability,” said Mr. Ken Loh, Chief Operating Officer of Pan-United Corporation Ltd. “Pan-United is excited to expand the use of the VERIFI® system in our fleet. This is an important step in leading the way to driving innovation deeper into the concrete industry, while enhancing efficiency and providing sustainable solutions to our customers,” added Mr. Loh.

About GCP Applied Technologies
GCP is a leading global provider of construction products technologies that include admixtures and additives for concrete and cement, the VERIFI® in-transit concrete management system, high-performance waterproofing products, and specialty construction products. GCP products have been used to build some of the world’s most renowned structures. More information is available at www.gcpat.com.

Investor Relations
Joseph DeCristofaro
T +1 617.498.2616
investors@gcpat.com

This announcement contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the context of the statement and generally arise when GCP or its management is discussing its beliefs, estimates or expectations. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “expects,” “estimates,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. These statements are not historical facts or guarantees of future performance but instead represent only the beliefs of GCP and its management at the time the statements were made regarding future events which are subject to certain risks, uncertainties and other factors, many of which are outside GCP’s control. Actual results and outcomes may differ materially from what is expressed or forecast in such forward-looking statements. Forward-looking statements include, without limitation, statements about expected financial positions; results of operations; cash flows; financing plans; business strategy; operating plans; strategic alternatives; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; and markets for securities. Like other businesses, we are subject to risks and uncertainties that could cause our actual results to differ materially from our projections or that could cause other forward-looking statements to prove incorrect. Factors that could cause actual results to materially differ from those contained in the forward-looking statements, or that could cause other forward-looking statements to prove incorrect, include, without limitation, risks related to: the cyclical and seasonal nature of the industries that GCP serves; foreign operations, especially in emerging regions; changes in currency exchange rates; the cost and availability of raw materials and energy; the effectiveness of GCP’s research and development, new product introductions and growth investments; acquisitions and divestitures of assets and gains and losses from dispositions; developments affecting GCP’s outstanding liquidity and indebtedness, including debt covenants and interest rate exposure; developments affecting GCP’s funded and unfunded pension obligations; warranty and product liability claims; legal proceedings; the inability to establish or maintain certain business relationships and relationships with customers and suppliers or the inability to retain key personnel; the handling of hazardous materials and the costs of compliance with environmental regulations; extreme weather events and natural disasters. These and other factors are identified and described in more detail in GCP’s Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available online at www.sec.gov, and subsequent quarterly reports. Readers are cautioned not to place undue reliance on GCP’s projections and other forward-looking statements, which speak only as of the date thereof. GCP undertakes no obligation to publicly release any revision to its projections and other forward-looking statements contained in this announcement, or to update them to reflect events or circumstances occurring after the date of this announcement.

Two New Liver Fibrosis Rodent Models Launched by Crown Bioscience

SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) — Crown Bioscience today announced the launch of two new liver fibrosis rodent models, allowing more rapid and cost-effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.

The two models encompass fibrosis induced by carbon tetrachloride and a new cholesterol-added, choline-deficient fibrosis (CCDF) diet. The launch of these models furthers CrownBio’s commitment to progressing NASH drug development by providing a wider breadth of preclinical platforms.

The new CCDF diet is a modification of the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) currently in preclinical use, featuring lower fat composition and added cholesterol. The resulting Wistar rat and C57BL/6 murine models display more severe liver injury than rodents on CDAHFD, with fibrosis observed in only six to nine weeks, and without the significant weight loss commonly observed in conventional chemical and nutritional deficit models.

Carbon tetrachloride induction provides rapid fibrosis models, allowing time and cost savings on preclinical studies compared with overnutrition and nutritional deficit models. Severe fibrosis is observed in as little as four weeks in C57BL/6 and Balb/c murine models, compared with 16 weeks or longer for industry standard overnutrition diets.

“Fibrosis is associated with more severe forms of NASH, so developing new platforms to model this disease aspect can help the patient populations worst affected by this silent disease,” said Dr. Jim Wang, Senior Vice President of Cardiovascular and Metabolic Disease at CrownBio. “These new models, along with other liver disease models including MS-NASH and CCl4 induced or modified rodent models, as well as NHP models, add to our vision of establishing a market-leading platform of highly translational models to accelerate NASH drug discovery.”

Characterization data on the novel CCDF model induced in the Wistar rat will be presented by CrownBio at the upcoming NASH Summit in Boston. The poster titled: ‘A Cholesterol Added, Choline Deficient Fibrogenic Diet Aggravates Liver Injury and Hepatic Steatosis in Wistar Rats’ will be presented to the NASH scientific community on May 5th 2020.

Later this year, CrownBio will also present data on a new diet-enhanced NHP model of liver steatosis, lipidemia, and insulin resistance, further enhancing the range of models available to NASH drug developers. Such advancements will allow the evaluation of potential therapeutics that reduce liver triglycerides and improve insulin resistance in models closely recapitulating human metabolic disease.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, metabolic disease, and inflammation research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

For more information visit:

https://www.crownbio.com
https://www.jsrlifesciences.com

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com

APEC reiterates commitment to prioritizing women’s role in economy

Jakarta (ANTARA) – The Asia-Pacific Economic Cooperation (APEC) forum marked International Women’s Day by reaffirming its commitment to prioritizing and promoting the role of women in the economy.

Such commitment will be implemented through initiatives that boost their access to capital, assets and markets, skills and capacity building, leadership opportunities, voice and agency, and access to innovation and technology, according to a written statement issued by the APEC Secretariat and received here on Monday.

“When we create an enabling environment for women to achieve their economic potential and contribute actively to the global economy, it is not only empowering but also beneficial,” Rebecca Sta Maria, the APEC Secretariat’s executive director, stated.

Sta Maria further remarked that the APEC had taken serious cognizance of the inclusion of women in the regional economy and striven to advance the economic integration of women for the last two decades.

Currently, the region’s labor force constitutes approximately 600 million women, with over 60 percent engaged in the formal sector.

However, the full potential of their contribution to the economy remains untapped. Moreover, women often take on informal work, such as caretaking and other domestic activities.

APEC member economies agreed to the La Serena Roadmap for Women and Inclusive Growth in 2019. The roadmap details directions and policy actions that will guide and drive members to enhance women’s economic participation in the region that will lead to more inclusive economic growth.

Administered by the APEC Policy Partnership on Women and the Economy, the roadmap seeks to encourage actions in five cross-cutting areas affecting economic growth for women.

Those five cross-cutting areas are: first, empowering women through access to capital and markets; second, strengthening women’s labor force participation; third, improving access of women to leadership positions in all levels of decision-making; fourth, supporting women’s education, training and skills development and access in a changing world of work; fifth, advancing women’s economic empowerment through data collection and analysis.

Depending on each APEC member economy’s social, economic, political, and legal circumstances, the roadmap puts forward four targets, including having laws, policies, and regulations in place by 2030 that prohibit discrimination on the basis of sex in employment access, opportunities, and conditions.

Another target is increasing the region’s gender balance among science, technology, engineering and mathematics graduates in tertiary education, and in research and development positions.

“Now, the APEC has concrete targets, such as putting in place laws, policies, and regulations that will provide equal access to capital and assets for both men and women and increase the region’s gender balance in leadership positions,” Sta Maria stated.

Malaysia, as the APEC host this year, will continually enhance women’s participation in the economy under its second priority of inclusive economic participation.

Source: ANTARA News